Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.43B P/E - EPS this Y 2.70% Ern Qtrly Grth -
Income -253.26M Forward P/E -7.74 EPS next Y 6.30% 50D Avg Chg -13.00%
Sales - PEG -0.18 EPS past 5Y - 200D Avg Chg -8.00%
Dividend N/A Price/Book 3.12 EPS next 5Y 41.70% 52W High Chg -27.00%
Recommedations 1.80 Quick Ratio 7.63 Shares Outstanding 90.98M 52W Low Chg 51.00%
Insider Own 3.42% ROA -37.13% Shares Float 70.90M Beta 1.09
Inst Own 104.67% ROE -64.31% Shares Shorted/Prior 10.93M/10.53M Price 17.81
Gross Margin - Profit Margin - Avg. Volume 690,312 Target Price 43.33
Oper. Margin - Earnings Date Nov 4 Volume 331,816 Change -0.34%
About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

Rocket Pharmaceuticals, Inc. News
09/17/24 Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease
09/10/24 Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors
09/09/24 Rocket Stock Down More Than 30% in Past Six Months: Here's Why
09/04/24 Rocket Pharmaceuticals (RCKT) Down 10.6% Since Last Earnings Report: Can It Rebound?
08/27/24 Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
08/25/24 Morgan Stanley Predicts up to 220% Jump for These 2 ‘Strong Buy’ Stocks
08/05/24 Rocket Pharmaceuticals: Q2 Earnings Snapshot
08/02/24 Should You Maintain Your Conviction in Rocket Pharmaceuticals (RCKT)?
07/01/24 FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
06/28/24 FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, Stock Slides
06/28/24 Rocket gene therapy rejected by FDA over manufacturing
06/28/24 Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel)
06/05/24 Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report?
05/31/24 Rocket Pharmaceuticals (NASDAQ:RCKT) Is In A Good Position To Deliver On Growth Plans
05/30/24 EC grants orphan medicinal product status to Rocket’s RP-A601
05/29/24 Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
05/10/24 Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
05/07/24 Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil
05/06/24 Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress
04/30/24 Rocket Pharmaceuticals (RCKT) Upgraded to Buy: Here's Why
RCKT Chatroom

User Image CaptObvious2014 Posted - 17 hours ago

$RCKT

User Image GSP Posted - 1 day ago

$PLCE $SAVA $GLMD $RCKT $U

User Image GSP Posted - 2 days ago

Day Trading Watch List Video for September 18th (con't): $GLMD $PLCE $RCKT $U $SAVA Watch here: https://greatstockpix.com/september-18th-day-trading-watch-list/

User Image BioRich Posted - 2 days ago

Looks like that AH movement was likely related to the pre-market news this morning regarding enrollment completion in their Phase II trial. Glad the market responded accordingly. Cheers! $RCKT

User Image BioRich Posted - 2 days ago

$RCKT Great news this morning regarding the Completion of Enrollment for Phase II Trial of RP-A501 and love the huge buy at market close. Definitely a good week for this beauty. Cheers!

User Image Stock_Titan Posted - 2 days ago

$RCKT Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease https://www.stocktitan.net/news/RCKT/rocket-pharmaceuticals-announces-completion-of-enrollment-in-phase-2-fju4f299ut5m.html

User Image BioRich Posted - 3 days ago

$RCKT

User Image BioRich Posted - 3 days ago

$RCKT nice AH movement. This slaps 20 tomorrow and closes above 20 Wednesday and Friday. Great things coming.

User Image Butters_Stotch1 Posted - 6 days ago

$RCKT and $GH sold both for a 8.5- 10 percent profit on each ticker

User Image Butters_Stotch1 Posted - 6 days ago

$GH and $RCKT

User Image Butters_Stotch1 Posted - 1 week ago

$RCKT and $GH both have good news… hopefully more green days to come

User Image briefingcom Posted - 1 week ago

$RCKT: Rocket Pharmaceuticals announces the appointment of Mikael Dolsten as an independent director to its Board of Directors

User Image Butters_Stotch1 Posted - 1 week ago

$RCKT moving in the right direction

User Image CaptObvious2014 Posted - 1 week ago

$RCKT my thesis was expecting a fairly aggressive short for~ 90 days past the June 28 news. This has held up considering volume. Im waiting for a SL raid. Maybe 16-15 before approval for an add. Happy with a 18 position.

User Image GringotsAG Posted - 1 week ago

$RCKT Having my eyes on this. Looking to add this week

User Image CaptObvious2014 Posted - 1 week ago

$RCKT do your worst, ill add

User Image PenkeTrading Posted - 1 week ago

I found you a Morning Star Candle Pattern on the daily chart of Rocket Pharmaceuticals Inc. $RCKT #RCKT #bullish #nasdaq #tradingsignals #technicalanalysis

User Image Forbes502 Posted - 2 weeks ago

$RCKT Planning to listen to presentation from Morgan Stanley event… If interested and not yet listened, here’s link to company webcast. 👀 https://ir.rocketpharma.com/events/event-details/morgan-stanley-22nd-annual-global-healthcare-conference

User Image MSBio Posted - 2 weeks ago

$RCKT I am lost One June 28, the company received CRL, claiming FDA requested limited CMC information, however, the company never mentioned re-submission, questions, 1. Is re-submission required? If re-submission not required, should the review time be shorter than 2 months? 2. If re-submission is required, did it occur already? If it did occur, is it classified as class I or II? Class I only requires 2 months of review time. Class II requires 6 months

User Image CaptObvious2014 Posted - 2 weeks ago

$RCKT 15.76 🎯 9/12/23 gap.

User Image Butters_Stotch1 Posted - 2 weeks ago

$RCKT averaged down…216 shares @18.47

User Image Butters_Stotch1 Posted - 2 weeks ago

$RCKT almost time to average down

User Image Telefon Posted - 2 weeks ago

$ELTP Elite Pharmaceuticals - Drugs Awaiting Launch and Total Market Value Methotrexate ($63.4M): Recently FDA approved, launching this quarter. Generic APAP with Codeine ($45M): Brand name Tylenol with Codeine, launching 6-8 weeks after Methotrexate. Oxy APAP ($500M): Generic Percocet, launching 6-8 weeks after APAP with Codeine. Hydro APAP ($477M): Generic Norco, launching after Oxy APAP. Methadone ($30M): Launching after Hydro APAP. Generic Vyvanse ($5.1B): Pending FDA approval, will take priority upon approval. Total Potential Market Value: $6.215 Billion $SPRY $ANIP $RCKT $SNDX

User Image MSBio Posted - 08/29/24

$RCKT Can RCKT provide some clarification? Did the company provide response to FDA requested information? Was it classified as class I or class II re-submission?

User Image CaptObvious2014 Posted - 08/28/24

$RCKT adding

User Image insidemoney Posted - 08/27/24

$RCKT Rocket Pharmaceuticals 14-Day RSI: 38.5 % from 52-Week Low: +22.9% % from 52-Week High: -42.8% Open Interest: 5,427 % Change: 0% Put/Call Ratio: 0.11 % Change: 0.0%

User Image NoFearHere Posted - 08/26/24

$RCKT lots of TUTE ownership is interesting

User Image NoFearHere Posted - 08/26/24

$RCKT alerted it's above trendline on watch to🚀🚀 Macd is primed to pop ,hence so will price RESIST 19.91+ 21.41+22.20

User Image tradingtwenty Posted - 08/26/24

$RCKT $RCKTW has trended 264 times in the past 24 hours (based on 5 minute intervals). Latest press release on Jun 28, 2024 07:27 AM: Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI™ (marnetegragene autotemcel; marne-cel) Link: https://tradingtwenty.com/news/525104/rocket-pharmaceuticals-provides-regulatory-update-on-kresladi-marnetegragene-autotemcel-marne-cel

User Image Briguy1 Posted - 08/26/24

$EQ $VKTX $RCKT - EQ (Equillium, Inc.) - interesting to see it still run, the ONO piece is the main driver but a very large one at that....GL

Analyst Ratings
Needham Buy Sep 17, 24
JP Morgan Overweight Aug 6, 24
Cantor Fitzgerald Overweight Aug 6, 24
Chardan Capital Buy Aug 6, 24
Needham Buy Aug 6, 24
Canaccord Genuity Buy Jul 3, 24
Chardan Capital Buy Jun 28, 24
Needham Buy Jun 28, 24
Needham Buy May 7, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Makker Gotham Director Director Nov 15 Sell 22.5323 20,000 450,646 1,296,497 11/16/23
Militello John See Remarks See Remarks Oct 20 Sell 17.062 564 9,623 8,760 10/25/23
Militello John See Remarks See Remarks Feb 17 Sell 19.06 1,076 20,509 1,782 10/20/23
Militello John See Remarks See Remarks Feb 17 Option 0 1,586 9,324 10/20/23
Makker Gotham Director Director Sep 28 Sell 21.09 14,989 316,118 1,316,497 10/02/23
Militello John See Remarks See Remarks Apr 21 Sell 18.65 2,342 43,678 5,636 04/25/23
Schwartz Jonathan David See Remarks See Remarks Feb 17 Sell 19.06 3,557 67,796 94,546 02/22/23
Shah Gaurav CEO CEO Feb 17 Sell 19.06 12,194 232,418 536,885 02/22/23
Schwartz Jonathan David See Remarks See Remarks Mar 30 Sell 16.1 135,000 2,173,500 89,529 04/04/22
Shah Gaurav CEO CEO Apr 01 Option 1.69 75,880 128,237 612,751 04/01/21
Patel Kinnari Chief Operating Offi.. Chief Operating Officer Mar 26 Option 1.45 93,962 136,245 188,939 03/26/21
Schwartz Jonathan David Chief Medical Office.. Chief Medical Officer Feb 03 Option 1.45 224,529 325,567 224,529 02/03/21